Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a company focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology.

The company’s first FDA approved product in the United States, the ReSure Sealant, is a synthetic ocular sealant designed for ophthalmic surgery. Ocular Therapeutix is currently in process of tailoring disease-specific ophthalmic drug release and plug delivery systems for the management and treatment of a wide range of anterior and posterior segment diseases.  To learn more, visit Ocular Therapeutix.

Vision Statement

To be the leading developer of sustained ophthalmic therapies with proprietary tailored hydrogels to improve patient experience and outcomes.